Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine 48-monatige Studie zur Bewertung der langfristigen Wirksamkeit von Elocta auf die Gesundheit der Gelenke (A-MORE)

18. September 2026 aktualisiert von: Swedish Orphan Biovitrum

Eine 48-monatige, multizentrische Beobachtungsstudie zur Bewertung der langfristigen Wirksamkeit von Elocta auf die Gelenkgesundheit

This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.

Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.

The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

427

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Berlin, Deutschland
        • Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
      • Bonn, Deutschland
        • Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
      • Frankfurt, Deutschland
        • Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
      • Frankfurt, Deutschland
        • Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
      • Hamburg, Deutschland
        • Universitätsklinikum Hamburg-Eppendorf (UKE)
      • Hanover, Deutschland
        • Medizinische Hochschule Hannover
      • Hanover, Deutschland
        • Werlhof-Institut für Hämostaseologie GmbH
      • Heidelberg, Deutschland
        • SRH-Klinikum Heidelberg
      • Mörfelden-Walldorf, Deutschland
        • HZRM Hämöphilie Zentrum Rhein Main
      • München, Deutschland
        • Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München
      • Tallinn, Estland
        • Lastehaigla, Tallinn (Tallinn Children´s Hospital)
      • Tallinn, Estland
        • The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
      • Helsinki, Finnland
        • Helsinki University Central Hospital, New Children Hospital
      • Turku, Finnland
        • Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
      • Thessaloniki, Griechenland
        • Ippokrateio Hospital Thessaloniki (adult department)
      • Thessaloniki, Griechenland
        • Ippokrateio Hospital Thessaloniki (pediatric department)
      • Bari, Italien
        • University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
      • Cesena, Italien
        • AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
      • Genova, Italien
        • Giannina Gaslini Institute
      • Milan, Italien
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
      • Parma, Italien
        • University Hospital of Parma, AOUP, Haemophilia Center
      • Rome, Italien
        • Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
      • Torino, Italien
        • Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
      • Groningen, Niederlande
        • University Medical Center Groningen/UMCG
      • Muscat, Oman
        • The Royal Hospital
      • Riyadh, Saudi-Arabien
        • Dr Suliman Al Habib Hospital Riyadh
      • Riyadh, Saudi-Arabien
        • King Faisal Specialised Hospital, KFSH Riyadh, Children
      • Riyadh, Saudi-Arabien
        • King Faisal Specialist Hospital KFSH, Adults
      • Riyadh, Saudi-Arabien
        • Riyadh Military Hospital (P.S.M.C)
      • Gothenburg, Schweden
        • Hematologimottagning Sahlgrenska
      • Malmö, Schweden
        • Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
      • Bern, Schweiz
        • Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
      • Lausanne, Schweiz
        • Service et Laboratoire central d'hématologie, Adults
      • Sankt Gallen, Schweiz
        • Zentrum für Labormedizin
      • Zurich, Schweiz
        • Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie
      • Ljubljana, Slowenien
        • University Medical Centre Ljubljana Division of Paediatrics
      • Barcelona, Spanien
        • Sant Johan De Deu
      • Barcelona, Spanien
        • Hospital de la Santa Creu i Sant Pau
      • Barcelona, Spanien
        • Hospital Vall d'Hebron
      • Cruces, Spanien
        • Hospital Universitario Cruces
      • Donostia / San Sebastian, Spanien
        • Hospital Universitario Donostia
      • Murcia, Spanien
        • Hospital Virgen de la Arrixaca
      • Málaga, Spanien
        • Hospital Universitario Carlos Haya
      • Navarro, Spanien
        • Complejo Hospitalario de Navarra
      • Oviedo, Spanien
        • Hospital Universitario Central de Asturias (HUCA)
      • Palma de Mallorca, Spanien
        • Hospital Universitario Son Espases
      • Seville, Spanien
        • Hospital Universitario Virgen del Rocío
      • Vigo, Spanien
        • Hospital Alvaro Cunqueiro
      • Brno, Tschechien
        • University Hospital Brno
      • Ostrava, Tschechien
        • University Hospital Ostrava
      • Prague, Tschechien
        • Dept. of Pediatric Haematology and Oncology, University Hospital Motol
      • Canterbury, Vereinigtes Königreich
        • East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
      • London, Vereinigtes Königreich
        • Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.

Beschreibung

Inclusion Criteria:

  • Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
  • Have a diagnosis of haemophilia A
  • At enrolment on prophylactic treatment with Elocta, independent of participation in the study

Exclusion Criteria:

  • Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
  • Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Hemophilia A patients

All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice.

Extended half-life factor VIII product

Andere Namen:
  • Efmoroctocog alfa
  • ELOCTATE
  • rFVIIIFc

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Joint health: Target joint development
Zeitfenster: 48 months

Number of target joints

48 months
Joint health: Target joint resolution
Zeitfenster: 48 months

Number of resolved target joints

48 months
Joint health: Target joint recurrence
Zeitfenster: 48 months

Number of recurring target joints

48 months
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
Zeitfenster: 48 months

Number of joint bleeding events per year, for treated bleeds

48 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
Zeitfenster: 48 months

The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome.

48 months
Global Gait Score, and/or joint score items for elbows, knees and ankles.
Zeitfenster: 48 months

The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles.

The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome.

48 months
Joint and physical evaluation for elbows, knees and ankles.
Zeitfenster: 48 months

The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome.

48 months

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
Zeitfenster: 48 months

Number of bleeding events per year, for treated bleeds

48 months
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
Zeitfenster: 48 months

Number of bleeding events per year, for all bleeds

48 months
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
Zeitfenster: 48 months

Percentage (%) of study population with zero (0) joint bleeds

48 months
Effectiveness of Elocta: Work productivity and impairment
Zeitfenster: 48 months

Assessed by WPAI-SHP questionnaire

48 months
Effectiveness of Elocta: Quality of Life
Zeitfenster: 48 months

Assessed by Haemo-QoL/Haem-A-QoL questionnaire

48 months
Effectiveness of Elocta: Physical activity level
Zeitfenster: 48 months

Assessed by the Saltin-Grimby scale

48 months
Effectiveness of Elocta: Quality of Life
Zeitfenster: 48 months

Assessed by EQ-5D-5L/EQ-5D-Y questionnaire

48 months
Effectiveness of Elocta: Severity of joint health
Zeitfenster: 48 months

Assessed by Patient Global Impression of Severity of Joint Health questionnaire

48 months
Effectiveness of Elocta: FVIII plasma levels
Zeitfenster: 48 months

Percentage (%) of FVIII plasma level

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Zeitfenster: 48 months

Assessed by medication dose

48 months
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
Zeitfenster: 48 months

Assessed by total number of exposure days per medication

48 months
Usage of Elocta: Annualised injection frequency per subject
Zeitfenster: 48 months

Assessed by prescription

48 months
Usage of Elocta: Annualised factor consumption per subject
Zeitfenster: 48 months

Assessed by prescription [IU/kg]

48 months
Usage of Elocta: Adherence
Zeitfenster: 48 months

Investigator assessed (Percentage (%))

48 months
Exploratory Objective
Zeitfenster: 48 months

Influence of different Elocta prophylaxis regimens on long term joint health

48 months
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
Zeitfenster: 48 months

Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level

48 months
Exploratory Objective: Explore adherence to prescribed treatment regimen
Zeitfenster: 48 months

florio HAEMO captured treatment adherence scores

48 months
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
Zeitfenster: 48 months

florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps)

48 months
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
Zeitfenster: 48 months

florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels

48 months
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
Zeitfenster: 48 months

florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Zeitfenster: 48 months

Target joint development, resolution and recurrence

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Zeitfenster: 48 months

Annualised joint bleeding rate (AJBR) for treated bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Zeitfenster: 48 months

Ultrasound (HEAD-US)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Zeitfenster: 48 months

Clinical joint scoring (HJHS)

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Zeitfenster: 48 months

Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Zeitfenster: 48 months

Occurrence of zero (0) joint bleeds

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Zeitfenster: 48 months

Quality of Life assessed by Haemo-QoL/Haem-A-QoL

48 months
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
Zeitfenster: 48 months

Physical activity level assessed by the Saltin-Grimby scale

48 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Study Physician, Swedish Orphan Biovitrum

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

30. März 2020

Primärer Abschluss (Tatsächlich)

4. Mai 2026

Studienabschluss (Tatsächlich)

4. Mai 2026

Studienanmeldedaten

Zuerst eingereicht

20. Februar 2020

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. März 2020

Zuerst gepostet (Tatsächlich)

3. März 2020

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

22. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

18. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • Sobi.Elocta-005

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .